OBJECTIVE: To study blood and bronchoalveolar lavage (BAL) fluid levels of platelet activating factor (PAF-acether) and phospholipase A2 (PLA2) in patients with septic shock or following severe trauma. DESIGN: Prospective controlled clinical study. SETTING: An intensive care unit (ICU) of a university hospital. PATIENTS AND PARTICIPANTS: The study comprised 12 patients, 8 with septic shock and 4 with trauma, consecutively admitted to the ICU. Healthy volunteers were used as controls. MEASUREMENTS AND RESULTS: Blood PAF-acether and plasma PLA2 levels were measured within 24 h after the patients arrival to the ICU. The Apache II score and outcome were registered. Median values for PAF-acether and PLA2 in the septic shock patients were 10.5 x 10(-10) M and 5300 units/ml, respectively, whereas corresponding values in the trauma patients were 1.3 x 10(-10) M and 770 units/ml. Normal healthy individuals had no detectable PAF-acether in the circulating blood (< 0.5 x 10(-10) M), and normal plasma PLA2 activity was < 300 units/ml. Moreover, both PLA2 and PAF-acether levels correlated well with the severity of the disease as assessed by the Apache II scoring system (p < 0.01 for PLA2 and p < 0.05 for PAF-acether). In addition, PAF-acether and PLA2 were determined in BAL fluid of patients with septic shock (n = 5) and trauma (n = 3); increased PAF-acether levels were found in four patients with septic shock and one patient with trauma. CONCLUSION: These results demonstrate a significant increase of both PLA2 and PAF-acether in the circulation of trauma patients, and a further increase in septic shock patients. It is possible that PAF-acether and PLA2 can be used as markers for the severity of the disease in septic shock and following severe trauma.
OBJECTIVE: To study blood and bronchoalveolar lavage (BAL) fluid levels of platelet activating factor (PAF-acether) and phospholipase A2 (PLA2) in patients with septic shock or following severe trauma. DESIGN: Prospective controlled clinical study. SETTING: An intensive care unit (ICU) of a university hospital. PATIENTS AND PARTICIPANTS: The study comprised 12 patients, 8 with septic shock and 4 with trauma, consecutively admitted to the ICU. Healthy volunteers were used as controls. MEASUREMENTS AND RESULTS: Blood PAF-acether and plasma PLA2 levels were measured within 24 h after the patients arrival to the ICU. The Apache II score and outcome were registered. Median values for PAF-acether and PLA2 in the septic shockpatients were 10.5 x 10(-10) M and 5300 units/ml, respectively, whereas corresponding values in the traumapatients were 1.3 x 10(-10) M and 770 units/ml. Normal healthy individuals had no detectable PAF-acether in the circulating blood (< 0.5 x 10(-10) M), and normal plasma PLA2 activity was < 300 units/ml. Moreover, both PLA2 and PAF-acether levels correlated well with the severity of the disease as assessed by the Apache II scoring system (p < 0.01 for PLA2 and p < 0.05 for PAF-acether). In addition, PAF-acether and PLA2 were determined in BAL fluid of patients with septic shock (n = 5) and trauma (n = 3); increased PAF-acether levels were found in four patients with septic shock and one patient with trauma. CONCLUSION: These results demonstrate a significant increase of both PLA2 and PAF-acether in the circulation of traumapatients, and a further increase in septic shockpatients. It is possible that PAF-acether and PLA2 can be used as markers for the severity of the disease in septic shock and following severe trauma.
Authors: A J Wardlaw; K F Chung; R Moqbel; A J MacDonald; A Hartnell; M McCusker; J V Collins; P J Barnes; A B Kay Journal: Am Rev Respir Dis Date: 1990-02
Authors: R M Kramer; C Hession; B Johansen; G Hayes; P McGray; E P Chow; R Tizard; R B Pepinsky Journal: J Biol Chem Date: 1989-04-05 Impact factor: 5.157
Authors: Seung Hyun Han; Je Hak Kim; Ho Seong Seo; Michael H Martin; Gook-Hyun Chung; Suzanne M Michalek; Moon H Nahm Journal: J Immunol Date: 2006-01-01 Impact factor: 5.422
Authors: Johanna Rivera; Rani S Sellers; Wangyong Zeng; Nico van Rooijen; Arturo Casadevall; David L Goldman Journal: J Biol Chem Date: 2014-01-29 Impact factor: 5.157